March 22, 2018 / 12:18 PM / 6 months ago

BRIEF-Health Canada Approves Rituxan Subcutaneous Formulation For Canadians With Chronic Lymphocytic Leukemia

March 22 (Reuters) - Roche Holding AG:

* HEALTH CANADA APPROVES RITUXAN® SUBCUTANEOUS FORMULATION FOR CANADIANS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

* ‍HOFFMANN-LA ROCHE - HEALTH CANADA APPROVES RITUXAN SC FORMULATION FOR CANADIANS WITH CHRONIC LYMPHOCYTIC LEUKEMIA​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below